Akademik Veri Yönetim Sistemi
Retina-Vitreus, cilt.26, sa.1, ss.52-57, 2017 (Scopus)
Aim of the Study: Analyzing the effectiveness of half-dose single treatment Photodynamic Therapy (PDT) which was implemented by using verteporfin in chronic central serous chorioretinopathy (CSCR) is the aim of this study. Material and Method: In this study, 34 patients'who have chronic CSCR 37 eyes were examined prospectively. Patients were given 3mg/m2 verteporfin and PTD was implemented to the areas where were identified in FFA and/or ICG by using the spot which is 1000 micron bigger than the active lesion's total diameter. Before and after the photodynamic therapy, in 1 week, 1 month and 6 month Central foveal thickness were measured by using full ophthalmoscopy and optical coherence tomography. The variation in Best Corrected Visual Acuity and Central Foveal Thickness is accepted as the criteria for effectiveness. Findings: This study focuses on 37 eyes of 34 patients who are 25 male and 9 female. The average age of patients is 48.5±8.4. The average follow-up time is 6.4±1.5 months. As a result of the Photodynamic therapy, it is observed that 51 %of patients had 2 rows or more visual recovery according to the Snellen visual acuity chart. While Best corrected visual acuity level were same for 27% of patients', 1 or more rows decrease were identified for 10% of patients. Before the photodynamic therapy, while the Central foveal thickness was 372.4±107.5 μ, after the photodynamic therapy the average central macular thickness was 220.97±76.4 μ (p<0.01). Before the Photodynamic Therapy, while 36 of 37 eyes had subretinal fluid, after the therapy only 10 eyes had subretinal fluid in 1 month. Discussion: In chronic central serous chorioretinopathy, the implementation of half dose verteporfin and PDT has provided good results in the anatomical and functional for 6 months and no significant side effects have been observed.